GlassScriptPhysician profile
John A Vischio
NPI 1417147406
$10,224.96
in general payments reported to CMS, 2019-2025
39 companies · $3,737 in 2025
The $3,737 reported for 2025 was more than what 82% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $526 · 2020: $109 · 2021: $396 · 2022: $553 · 2023: $1,186 · 2024: $3,719 · 2025: $3,737.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,539 · Education: $103.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,538.78 |
| Education | $103.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,826.50 | 2019-2025 | Rinvoq, Skyrizi, Humira |
| Amgen INC. | $964.82 | 2019-2025 | Tavneos, Uplizna, Enbrel |
| Janssen Biotech, INC. | $945.74 | 2019-2025 | Tremfya |
| Mallinckrodt Hospital Products INC. | $714.33 | 2021-2025 | Acthar |
| Ucb, INC. | $663.94 | 2019-2025 | Bimzelx, Cimzia |
| Novartis Pharmaceuticals Corporation | $505.47 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $417.62 | 2022-2025 | Orencia |
| Glaxosmithkline, LLC. | $383.79 | 2019-2025 | Benlysta |
| Pfizer INC. | $332.92 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $309.56 | 2021-2025 | Saphnelo |
| Genzyme Corporation | $244.92 | 2024-2025 | |
| Kiniksa Pharmaceuticals International, Plc | $227.06 | 2024 | Arcalyst |
| Genentech USA, INC. | $226.85 | 2021-2025 | Actemra, Gazyva |
| Lilly USA, LLC | $190.99 | 2021-2025 | Taltz, Zepbound, Omvoh |
| Aurinia Pharma U.S., INC. | $164.89 | 2023-2025 | Lupkynis |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Octapharma USA, INC. | $157.03 | 2024-2025 | Octagam Immune Globulin (Human) |
| Horizon Therapeutics Plc | $94.56 | 2019-2022 | |
| Ani Pharmaceuticals, INC. | $87.72 | 2023-2024 | Purified Cortrophin Gel |
| Boehringer Ingelheim Pharmaceuticals, INC. | $82.22 | 2023-2025 | Ofev, Cyltezo |
| Sandoz INC. | $77.18 | 2023-2024 | Hyrimoz |
| Sobi, INC | $75.81 | 2023-2025 | |
| Actelion Pharmaceuticals US, INC. | $67.56 | 2024-2025 | Opsumit, Opsynvi |
| Alexion Pharmaceuticals, INC. | $66.87 | 2023-2025 | Strensiq, Ultomiris |
| Fresenius Kabi USA, LLC | $61.92 | 2024-2025 | Idacio |
| Organon LLC | $50.77 | 2024-2025 | Hadlima |
| Takeda Pharmaceuticals U.S.A., INC. | $35.88 | 2024 | Hyqvia |
| Janssen Scientific Affairs, LLC | $31.77 | 2019 | |
| Kiniksa Pharmaceuticals, LTD. | $28.81 | 2021-2023 | Arcalyst |
| Invivyd INC | $25.22 | 2025 | Pemgarda |
| Scilex Pharmaceuticals INC. | $24.52 | 2025 | |
| Novo Nordisk INC | $20.70 | 2024 | Wegovy |
| Fidia Pharma USA INC. | $20.19 | 2019 | |
| Alvogen INC | $18.61 | 2025 | Teriparatide |
| Endo USA, INC. | $15.53 | 2024 | Xiaflex |
| Almatica Pharma LLC | $13.75 | 2025 | Teriparatide |
| Janssen Pharmaceuticals, INC | $13.17 | 2025 | Tremfya |
| Mallinckrodt Enterprises LLC | $12.76 | 2019 | |
| Bioventus LLC | $12.04 | 2021 | |
| Pacira Therapeutics, INC. | $10.97 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Vischio listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.